CMND News & Events

Stock futures are modestly positive this morning. Markets are stabilizing and leaning cautiously higher as investors shift from escalation fears to tentative optimism around renewed U.S.-Iran diplomacy. Crude has slipped back below the $100 level as signals emerge that both sides are considering another round of negotiations, easing immediate supply fears tied to the Strait of Hormuz. Global markets are higher, with U.S. indices pushing back toward pre-war levels, supported by tech strength and early earnings from major banks. However, the U.S. naval blockade is still in place, oil flows remain disrupted, and the broader energy shock has not been resolved.In pre-market trading, S&P 500 futures rose 0.27%, Nasdaq futures rose 0.53% and Dow futures rose 0.07%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Globalstarup 11% after entering into a definitive merger agreement under which Amazonwill acquire the company for $90.00 per shareAmerican Airlinesand United Airlinesup 8% and 2%, respectively, after BloombergUnited Airlines CEO Scott Kirby has floated a potential merger with AmericanNovo Nordisk (NVO) up 3% after announcing a strategic partnership with OpenAI to speed drug developmentUP AFTER EARNINGS -Citiup 1%BlackRockup 1%DOWN AFTER EARNINGS -Johnson & Johnsondown 2%Wells Fargodown 2%JPMorgandown 1%LOWER -Clearmind Medicinedown 33% after reporting that CMND-100, the company's non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder, has met the primary endpoint in its Phase I/IIa clinical trial

Clearmind Medicine announced that CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial. Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to date. The data demonstrated that the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and continued favorable overall tolerability, consistent with the safety outcomes observed in prior cohorts. The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Meeting the primary safety and tolerability endpoint in this dose-escalation stage, including at the higher dosage in the third cohort, supports continued advancement of CMND-100 as a potential novel, non-hallucinogenic treatment option for AUD.

Clearmind Medicine announced the successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder. This milestone reflects continued positive progress and strong momentum in the multinational, multicenter study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The company also announced that four additional participants have been successfully treated at the clinical center in Tel Aviv, further expanding enrollment and demonstrating the operational strength of the Israeli sites in the trial.